SFI
KLDO

Susquehanna Fundamental Investments’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Susquehanna Fundamental Investments’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-24,398
Closed -$222K – 1664
2020
Q4 		$222K Buy
24,398
+6,543
+37% +$53.7K ﹤0.01% 1343
2020
Q3 		$198K Buy
17,855
+2,811
+19% +$19.5K 0.01% 1198
2020
Q2 		$112K Buy
+15,044
New +$101K 0.01% 898

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna Fundamental Investments's KLDO Position: Q1 2021 in Review

Susquehanna Fundamental Investments sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q1 2021, closing a stake of 24,398 shares — an estimated $222K sold.

Susquehanna Fundamental Investments first reported a position in KLDO in Q2 2020 and held it in 3 quarters. The position peaked at $222K in Q4 2020. 71 funds tracked by Wall St. Rank hold KLDO as of Q1 2021.

  • Susquehanna Fundamental Investments reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 24,398 Kaleido Biosciences, Inc. Common Stock shares in Q1 2021, an estimated $222K.
  • Susquehanna Fundamental Investments first reported a position in Kaleido Biosciences, Inc. Common Stock in Q2 2020 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Kaleido Biosciences, Inc. Common Stock position peaked at $222K in Q4 2020.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q1 2021.

Based on Susquehanna Fundamental Investments's 13F filing for Q1 2021, filed 17 May 2021.